We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

4 hedge funds and large institutions have $861K invested in Traws Pharma in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% less capital invested

Capital invested by funds: $1.18M → $861K (-$317K)

64% less funds holding

Funds holding: 11 → 4 (-7)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
4
Holders Change
-7
Holders Change %
-63.64%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$112K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$112K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$367K
2
Citigroup
Citigroup
New York
-$56.2K
3
DLA
Douglas Lane & Associates
New York
-$41K
4
BFA
BlackRock Fund Advisors
California
-$28.1K
5
Deutsche Bank
Deutsche Bank
Germany
-$28.1K

TRAW Hedge Fund Activity: Q2 2016 in Review

4 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2016, worth a combined $861K — down 27% from $1.18M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TRAW and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $112K. The largest seller was Anson Funds Management, exiting entirely with an estimated $367K sold.

  • 4 institutional investors held Traws Pharma (TRAW) as of Q2 2016, down from 11 in Q1 2016.
  • Funds reported $861K of Traws Pharma stock for Q2 2016, down 27% quarter-over-quarter.
  • 0 funds opened new Traws Pharma positions in Q2 2016 and 7 closed out, a net change of -7 holders.
  • The largest Traws Pharma buyer in Q2 2016 was Renaissance Technologies, an estimated $112K added.
  • The largest Traws Pharma seller in Q2 2016 was Anson Funds Management, an estimated $367K sold.

Based on aggregated 13F filings for Q2 2016.